Evotec SE (EVO) Shares Outstanding (2009 - 2026)
Evotec SE (EVO) posted Shares Outstanding (Entity) of $177.6 million for Q4 2025, little changed sequentially from $177.7 million in Q3 2025, and little changed YoY from $177.3 million in Q4 2024.
Evotec SE (EVO) Shares Outstanding (2009 - 2026) Analysis & Trends
Evotec SE has reported Shares Outstanding (Entity) for 9 years, with the latest figure at $177.6 million in Q4 2025.
- Quarterly Shares Outstanding (Entity) changed 0.16% year-over-year to $177.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $177.6 million (changed 0.16% YoY) and the FY2025 annual result came in at $177.6 million, changed 0.16% from the prior year.
- Shares Outstanding (Entity) was little changed at $177.6 million in Q4 2025 per EVO's latest filing, from $177.7 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $177.7 million in Q3 2025 and troughed at $164.1 million in Q1 2021.
- A 5-year average of $174.5 million and a median of $176.9 million in 2023 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2021 and 2023: Shares Outstanding (Entity) advanced 8.92% in 2021, then advanced 0.13% in 2023.
- Over 5 years, Shares Outstanding (Entity) stood at $164.5 million in 2021, then advanced by 7.38% to $176.7 million in 2022, then gained by 0.14% to $176.9 million in 2023, then gained by 0.21% to $177.3 million in 2024, then rose by 0.16% to $177.6 million in 2025.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $177.6 million, $177.7 million, and $177.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 4.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 1.17 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 417.60 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 1.58 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.60 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 1.16 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 101.00 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 499.50 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 832.44 Mn |
| 10 | Evotec SE | 692.56 Mn | 692.08 Mn | - | 355.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 177.58 Mn |
| Dec 31, 2025 | 177.58 Mn |
| Sep 30, 2025 | 177.67 Mn |
| Jun 30, 2025 | 177.56 Mn |
| Mar 31, 2025 | 177.30 Mn |
| Dec 31, 2024 | 177.30 Mn |
| Sep 30, 2024 | 177.35 Mn |
| Jun 30, 2024 | 176.92 Mn |
| Mar 31, 2024 | 176.92 Mn |
| Dec 31, 2023 | 176.92 Mn |
| Sep 30, 2023 | 176.94 Mn |
| Jun 30, 2023 | 176.94 Mn |
| Mar 31, 2023 | 176.67 Mn |
| Dec 31, 2022 | 176.67 Mn |
| Sep 30, 2022 | 176.70 Mn |
| Jun 30, 2022 | 176.70 Mn |
| Mar 31, 2022 | 176.70 Mn |
| Dec 31, 2021 | 166.41 Mn |
| Sep 30, 2021 | 164.53 Mn |
| Jun 30, 2021 | 164.33 Mn |